Literature DB >> 30108948

Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT2 and α1 receptor antagonists.

Hui Li Heng1, Chin Fei Chee1,2, Sek Peng Chin1,2, Yifan Ouyang3, Hao Wang3, Michael J C Buckle1, Deron R Herr4, Ian C Paterson5, Stephen W Doughty6, Noorsaadah Abd Rahman2, Lip Yong Chung1.   

Abstract

In this study, the (S)-enantiomers of the aporphine alkaloids, nuciferine and roemerine, were prepared via a synthetic route involving catalytic asymmetric hydrogenation and both stereoisomers were evaluated in vitro for functional activity at human 5-HT2 and adrenergic α1 receptor subtypes using a transforming growth factor-α shedding assay. Both enantiomers of each of the compounds were found to act as antagonists at 5-HT2 and α1 receptors. (R)-roemerine was the most potent compound at 5-HT2A and 5-HT2C receptors (pKb = 7.8-7.9) with good selectivity compared to (S)-roemerine at these two receptors and compared to its activity at 5-HT2B, α1A, α1B and α1D receptors.

Entities:  

Year:  2018        PMID: 30108948      PMCID: PMC6072365          DOI: 10.1039/c7md00629b

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  25 in total

1.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors.

Authors:  B L Roth; M Shoham; M S Choudhary; N Khan
Journal:  Mol Pharmacol       Date:  1997-08       Impact factor: 4.436

Review 2.  Advances in development of dopaminergic aporphinoids.

Authors:  Ao Zhang; Yi Zhang; Alan R Branfman; Ross J Baldessarini; John L Neumeyer
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

3.  Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.

Authors:  Shashikanth Ponnala; Junior Gonzales; Nirav Kapadia; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2014-03-04       Impact factor: 2.823

4.  Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.

Authors:  Shashikanth Ponnala; Nirav Kapadia; Sudharshan Madapa; Ian L Alberts; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2015-10-09       Impact factor: 2.823

5.  Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations.

Authors:  S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.

Authors:  Sandeep Chaudhary; Shashikanth Ponnala; Onica Legendre; Junior A Gonzales; Hernán A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2011-08-18       Impact factor: 3.641

7.  Structure-based identification of aporphines with selective 5-HT(2A) receptor-binding activity.

Authors:  Vani Munusamy; Beow Keat Yap; Michael J C Buckle; Stephen W Doughty; Lip Yong Chung
Journal:  Chem Biol Drug Des       Date:  2012-11-14       Impact factor: 2.817

8.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

9.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

10.  TGFα shedding assay: an accurate and versatile method for detecting GPCR activation.

Authors:  Asuka Inoue; Jun Ishiguro; Hajime Kitamura; Naoaki Arima; Michiyo Okutani; Akira Shuto; Shigeki Higashiyama; Tomohiko Ohwada; Hiroyuki Arai; Kumiko Makide; Junken Aoki
Journal:  Nat Methods       Date:  2012-09-16       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.